{"id":"calcitonin","rwe":[{"pmid":"41911648","year":"2026","title":"Insight into the interaction of heme with human calcitonin (hCT) and its inhibitory effect on hCT aggregation.","finding":"","journal":"Journal of inorganic biochemistry","studyType":"Clinical Study"},{"pmid":"41906924","year":"2026","title":"The Role of Calcitonin Gene-Related Peptide in High-Altitude Headache: A Prospective Field Study.","finding":"","journal":"Annals of clinical and translational neurology","studyType":"Clinical Study"},{"pmid":"41896726","year":"2026","title":"Efficacy of coadministration of calcitonin and hyperbaric bupivacaine in spinal anesthesia for unilateral open inguinal hernia repair in tramadol abuse patients: a randomized controlled trial.","finding":"","journal":"BMC anesthesiology","studyType":"Clinical Study"},{"pmid":"41896381","year":"2026","title":"Proteomic profiling and pathway analyses reveal molecular signatures and immune networks in pediatric sepsis.","finding":"","journal":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","studyType":"Clinical Study"},{"pmid":"41892600","year":"2026","title":"Predictors of Response to Occipital Nerve Stimulation in Patients with Refractory Chronic Cluster Headache: Protocol for a Prospective Observational Study.","finding":"","journal":"Brain sciences","studyType":"Clinical Study"}],"_fda":{"id":"961dd1fa-b9e5-45fe-8e14-3046d4d87422","set_id":"0365ebf8-0cb6-49ce-bfde-707d42b9ab00","openfda":{"nui":["M0003145","N0000175942"],"unii":["7SFC6U2VI5"],"route":["INTRAMUSCULAR","SUBCUTANEOUS"],"rxcui":["308866"],"spl_id":["961dd1fa-b9e5-45fe-8e14-3046d4d87422"],"brand_name":["CALCITONIN SALMON"],"spl_set_id":["0365ebf8-0cb6-49ce-bfde-707d42b9ab00"],"package_ndc":["70710-1875-1"],"product_ndc":["70710-1875"],"generic_name":["CALCITONIN SALMON"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Calcitonin [CS]"],"substance_name":["CALCITONIN SALMON"],"pharm_class_epc":["Calcitonin [EPC]"],"manufacturer_name":["Zydus Pharmaceuticals USA Inc."],"application_number":["ANDA215864"],"is_original_packager":[true]},"version":"1","pregnancy":["8.1 Pregnancy Risk Summary There are no studies with calcitonin salmon injection in pregnant women to inform a drug associated risk for birth defects or miscarriage. In an animal reproduction study, subcutaneous administration of calcitonin salmon to pregnant rabbits during organogenesis at 4-18 times the recommended parenteral human dose caused a decrease in fetal birth weights. No adverse developmental outcome was observed in the rat with subcutaneous administration of calcitonin salmon at 9 times the recommended human parenteral dose based on body surface area (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Calcitonin salmon has been shown to cause a decrease in fetal birth weights in rabbits when given by subcutaneous injection in doses 4 to 18 times the parenteral dose recommended for human use (of 54 International Units/m 2 ). No embryo/fetal toxicities related to calcitonin salmon were reported from maternal subcutaneous daily doses in rats up to 80 International Units/kg/day from gestation day 6 to 15."],"overdosage":["10 OVERDOSAGE The pharmacologic actions of calcitonin salmon injection suggest that hypocalcemic tetany could occur in overdose. Therefore, provisions for parenteral administration of calcium should be available for the treatment of overdose. A dose of calcitonin salmon l000 International Units subcutaneously may produce nausea and vomiting. Doses of 32 International Units per kg per day for 1 to 2 days demonstrate no other adverse effects. Data on chronic high-dose administration are insufficient to assess toxicity."],"description":["11 DESCRIPTION Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and fish. Calcitonin salmon injection, USP, synthetic is a synthetic polypeptide of 32 amino acids in the same linear sequence that is found in calcitonin of salmon origin. This is shown by the following graphic formula: It is provided in sterile solution for subcutaneous or intramuscular injection. Each milliliter contains: calcitonin salmon, 200 USP Units. Inactive Ingredients (per mL): acetic acid, USP, 2.25 mg; phenol, USP, 5 mg; sodium acetate trihydrate, USP, 2 mg; sodium chloride, USP, 7.5 mg; water for injection, USP. The activity of calcitonin salmon injection is stated in International Units based on bioassay in comparison with the International Reference Preparation of calcitonin salmon for Bioassay, distributed by the National Institute for Biological Standards and Control, Holy Hill, London. Image"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Calcitonin salmon injection, USP, synthetic is available as a clear, colorless, sterile solution in individual 2 mL multiple-dose vials containing 200 USP Units per mL. NDC 70710-1875-1 carton containing 1 x 2 mL multiple-dose vial Storage and Handling Store in a refrigerator between 2° to 8°C (36° to 46°F). Protect from freezing."],"geriatric_use":["8.5 Geriatric Use Clinical studies of calcitonin salmon injection did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20260306","clinical_studies":["14 CLINICAL STUDIES 14.1 Paget’s Disease of Bone The trials used for the basis of approval for calcitonin salmon injection for treatment of Paget's disease of bone were conducted in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. In open-label clinical trials of several months to two years duration with historical controls, biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. There is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss is improved infrequently (4 of 29 patients studied by audiometry). Patients with increased cardiac output due to extensive Paget's disease of bone have had measured decreases in cardiac output while receiving calcitonin salmon. The number of treated patients in this category is too small to predict how likely such a result will be. There is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. 14.2 Hypercalcemia In four open-label clinical trials enrolling 53 patients, calcitonin salmon has been shown to lower elevated serum calcium levels of patients with carcinoma (with or without metastases), multiple myeloma, and primary hyperparathyroidism (lesser response). These patients were treated with calcitonin salmon only when other methods of lowering serum calcium (hydration, oral phosphate, corticosteroids) were unsuccessful or unsuitable. With patients' pre-therapy serum calcium levels as controls, reduction in serum calcium was evident within 1 to 2 hours of administration. The peak effect occurred within 24 to 48 hours of injection and administration of calcitonin salmon every 12 hours maintained a hypocalcemic effect for approximately 5 to 8 days, the time period evaluated for most patients in the clinical trials. The average reduction of 8-hour post-injection serum calcium was approximately 9% (2 to 3 mg/dL). Patients with higher values of serum calcium tended to show greater reductions during calcitonin salmon treatment. 14.3 Postmenopausal Osteoporosis The trials used for the basis of approval for calcitonin salmon injection for treatment of postmenopausal osteoporosis were two randomized, open-label, 2-year studies in postmenopausal women 50 to 74 years of age with total body calcium < 85% of expected normal, and vertebral osteopenia (by x-ray criteria) and/or at least one atraumatic compression fracture. The primary efficacy endpoint was total body calcium measured by neutron activation analysis. Patients were randomized to calcitonin salmon injection 100 International Units daily (subcutaneously or intramuscularly) at bedtime, or control. All subjects received daily supplements of 1,200 mg calcium carbonate and 400 International Units of vitamin D. In both studies, total body calcium increased from baseline with calcitonin salmon therapy at 1 year, followed by a trend to decreasing total body calcium (still above baseline) at 2 years. Thoracic and lumbar spine X-rays (AP/lateral) were obtained yearly. For the two studies combined (34 calcitonin salmon and 35 control subjects), in the first year there was a total of 6 new vertebral compression fractures in the calcitonin salmon group and 5 in the control group. In the second year there were 7 new fractures in each group. No evidence currently exists to indicate whether calcitonin salmon injection decreases the risk of osteoporotic fracture. A controlled study, which was prematurely discontinued, failed to demonstrate any benefit of calcitonin salmon on fracture rate. No adequate controlled trials have examined the effect of calcitonin salmon injection on vertebral bone mineral density beyond 1 year of treatment. Therefore, the minimum effective dose of calcitonin salmon injection for prevention of vertebral bone mineral density loss has not been established. In clinical studies of postmenopausal osteoporosis, bone biopsy and radial bone mass assessments at baseline and after 26 months of daily injectable calcitonin salmon indicate that calcitonin therapy results in the formation of normal bone."],"pharmacodynamics":["12.2 Pharmacodynamics Bone Single injections of calcitonin salmon caused a marked transient inhibition of the ongoing bone resorptive process. With prolonged use, there is a persistent, smaller decrease in the rate of bone resorption. Histologically, this is associated with a decreased number of osteoclasts and an apparent decrease in their resorptive activity. In healthy adults, who have a relatively low rate of bone resorption, the administration of exogenous calcitonin salmon results in decreases in serum calcium within the limits of the normal range. In healthy children and in patients whose bone resorption is more rapid, decreases in serum calcium are more pronounced in response to calcitonin salmon. Kidney Studies with injectable calcitonin salmon show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption. Gastrointestinal Tract Some evidence from studies with injectable preparations suggests that calcitonin salmon may have effects on the gastrointestinal tract. Short-term administration of injectable calcitonin salmon results in marked transient decreases in the volume and acidity of gastric juice and in the volume and the trypsin and amylase content of pancreatic juice. Whether these effects continue to be elicited after each injection of calcitonin salmon during chronic therapy has not been investigated."],"pharmacokinetics":["12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively. After subcutaneous administration, peak plasma levels are reached in approximately 23 minutes. The terminal half-life is approximately 58 minutes for intramuscular administration and 59 to 64 minutes for subcutaneous administration. The apparent volume of distribution is 0.15 to 0.3 L/kg."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity Reactions, including anaphylaxis [see Warnings and Precautions ( 5.1 )] Hypocalcemia [see Warnings and Precautions ( 5.2 )] Malignancy [see Warnings and Precautions ( 5.3 )] Most common adverse reactions are nausea with or without vomiting (10%), injection site inflammation (10%), and flushing of the face or hands (2% to 5%) ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of calcitonin salmon injection was assessed in open-label trials several months to two years in duration. The most common adverse reactions are discussed below. Nausea Nausea with or without vomiting has been noted in about 10% of patients treated with calcitonin salmon. It is most evident when treatment is first initiated and tends to decrease or disappear with continued administration. Dermatologic Reactions Local inflammatory reactions at the site of subcutaneous or intramuscular injection have been reported in about 10% of patients. Flushing of face or hands occurred in about 2% to 5% of patients. Skin rashes and pruritus of the ear lobes have also been reported. Other Adverse Reactions Nocturia, feverish sensation, pain in the eyes, poor appetite, abdominal pain, pedal edema, and salty taste have been reported in patients treated with calcitonin salmon injection. Malignancy A meta-analysis of 21 randomized, controlled clinical trials with calcitonin salmon (nasal spray or investigational oral formulations) was conducted to assess the risk of malignancies in calcitonin salmon-treated patients compared to placebo-treated patients. The trials in the meta-analysis ranged in duration from 6 months to 5 years and included a total of 10883 patients (6151 treated with calcitonin salmon and 4732 treated with placebo). The overall incidence of malignancies reported in these 21 trials was higher among calcitonin salmon-treated patients (254/6151 or 4.1%) compared with placebo-treated patients (137/4732 or 2.9%). Findings were similar when analyses were restricted to the 18 nasal spray only trials [calcitonin salmon 122/2712 (4.5%); placebo 30/1309 (2.3%)]. The meta-analysis results suggest an increased risk of overall malignancies in calcitonin salmon-treated patients compared to placebo-treated patients when all 21 trials are included and when the analysis is restricted to the 18 nasal spray only trials (see Table 1). It is not possible to exclude an increased risk when calcitonin salmon is administered by the subcutaneous, intramuscular, or intravenous route because these routes of administration were not investigated in the meta-analysis. The increased malignancy risk seen with the meta-analysis was heavily influenced by a single large 5-year trial, which had an observed risk difference of 3.4% [95% CI (0.4%, 6.5%)]. Imbalances in risks were still observed when analyses excluded basal cell carcinoma (see Table 1); the data were not sufficient for further analyses by type of malignancy. A mechanism for these observations has not been identified. Although a definitive causal relationship between calcitonin salmon use and malignancies cannot be established from this meta-analysis, the benefits for the individual patient should be carefully evaluated against all possible risks [see Warnings and Precautions ( 5.3 )]. Table 1: Risk Difference for Malignancies in Calcitonin Salmon-Treated Patients Compared with Placebo-Treated Patients * The overall adjusted risk difference is the difference between the percentage of patients who had any malignancy (or malignancy excluding basal cell carcinoma) in calcitonin salmon and placebo treatment groups, using the Mantel-Haenszel (MH) fixed-effect method. A risk difference of 0 is suggestive of no difference in malignancy risks between the treatment groups. † The corresponding 95% confidence interval for the overall adjusted risk difference also based on MH fixed-effect method. Patients Malignancies Risk Difference * (%) 95% Confidence Interval † (%) All (nasal spray + oral) All 1.0 (0.3, 1.6) All (nasal spray + oral) Excluding basal cell carcinoma 0.5 (-0.1, 1.2) All (nasal spray only) All 1.4 (0.3, 2.6) All (nasal spray only) Excluding basal cell carcinoma 0.8 (-0.2, 1.8) 6.2 Postmarketing Experience Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been reported during post-approval use of calcitonin salmon injection. Allergic / Hypersensitivity Reactions: Serious hypersensitivity reactions have been reported in patients receiving calcitonin salmon injection, e.g., bronchospasm, swelling of the tongue or throat, anaphylactic shock, and death due to anaphylaxis. Skin and subcutaneous tissue disorders : Urticaria Hypocalcemia : Hypocalcemia with tetany (i.e. muscle cramps, twitching) and seizure activity have been reported. Body as a Whole: influenza-like symptoms, fatigue, edema (facial, peripheral, and generalized) Musculoskeletal: arthralgia, musculoskeletal pain Cardiovascular: hypertension Gastrointestinal: abdominal pain, diarrhea Urinary System: polyuria Nervous System: dizziness, headache, paresthesia, tremor Vision: visual disturbance 6.3 Immunogenicity Consistent with the potentially immunogenic properties of medicinal products containing peptides, administration of calcitonin salmon may trigger the development of anti-calcitonin antibodies. Circulating antibodies to calcitonin salmon after 2 to 18 months of treatment have been reported in about one-half of the patients with Paget's disease in whom antibody studies were done. In some cases, high antibody titers are found; these patients usually will have a loss of response to treatment [see Warnings and Precautions ( 5.4 )]. The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of a positive antibody test result may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of antibodies among different calcitonin salmon products may be misleading."],"contraindications":["4 CONTRAINDICATIONS Hypersensitivity to calcitonin salmon or any of the excipients. Reactions have included anaphylaxis with death, bronchospasm, and swelling of the tongue or throat [see Warnings and Precautions ( 5.1 )]. Hypersensitivity to calcitonin salmon or any of the excipients ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS No formal drug interaction studies have been performed with calcitonin salmon injection. Concomitant use of calcitonin salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may require adjustment. Concomitant use of calcitonin salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may require adjustment ( 7 )"],"mechanism_of_action":["12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts. 12.2 Pharmacodynamics Bone Single injections of calcitonin salmon caused a marked transient inhibition of the ongoing bone resorptive process. With prolonged use, there is a persistent, smaller decrease in the rate of bone resorption. Histologically, this is associated with a decreased number of osteoclasts and an apparent decrease in their resorptive activity. In healthy adults, who have a relatively low rate of bone resorption, the administration of exogenous calcitonin salmon results in decreases in serum calcium within the limits of the normal range. In healthy children and in patients whose bone resorption is more rapid, decreases in serum calcium are more pronounced in response to calcitonin salmon. Kidney Studies with injectable calcitonin salmon show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption. Gastrointestinal Tract Some evidence from studies with injectable preparations suggests that calcitonin salmon may have effects on the gastrointestinal tract. Short-term administration of injectable calcitonin salmon results in marked transient decreases in the volume and acidity of gastric juice and in the volume and the trypsin and amylase content of pancreatic juice. Whether these effects continue to be elicited after each injection of calcitonin salmon during chronic therapy has not been investigated. 12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively. After subcutaneous administration, peak plasma levels are reached in approximately 23 minutes. The terminal half-life is approximately 58 minutes for intramuscular administration and 59 to 64 minutes for subcutaneous administration. The apparent volume of distribution is 0.15 to 0.3 L/kg."],"indications_and_usage":["1 INDICATIONS AND USAGE Calcitonin salmon injection, synthetic is a calcitonin, indicated for the following conditions: Treatment of symptomatic Paget's disease of bone when alternative treatments are not suitable ( 1.1 ) Treatment of hypercalcemia ( 1.2 ) Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.3 ) Limitations of Use: Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4 , 5.3 ) 1.1 Treatment of Paget’s Disease of Bone Calcitonin salmon injection is indicated for the treatment of symptomatic Paget's disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. There is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. Calcitonin salmon injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). 1.2 Treatment of Hypercalcemia Calcitonin salmon injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. 1.3 Treatment of Postmenopausal Osteoporosis Calcitonin salmon injection is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. The evidence of efficacy for calcitonin salmon injection is based on increases in total body calcium observed in clinical trials. Fracture reduction efficacy has not been demonstrated. Calcitonin salmon injection should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). 1.4 Important Limitations of Use Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see Warnings and Precautions ( 5.3 )]."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious hypersensitivity reactions, including reports of fatal anaphylaxis have been reported. Consider skin testing prior to treatment in patients with suspected hypersensitivity to calcitonin salmon ( 5.1 ) Hypocalcemia has been reported. Ensure adequate intake of calcium and vitamin D ( 5.2 ) Malignancy: A meta-analysis of 21 clinical trials suggests an increased risk of overall malignancies in calcitonin salmon-treated patients ( 5.3 , 6.1 ) Circulating antibodies to calcitonin salmon may develop, and may cause loss of response to treatment ( 5.4 ) 5.1 Hypersensitivity Reactions Serious hypersensitivity reactions have been reported in patients receiving calcitonin salmon injection, e.g., bronchospasm, swelling of the tongue or throat, anaphylactic shock, and death due to anaphylaxis. Appropriate medical support and monitoring measures should be readily available when calcitonin salmon injection is administered. If anaphylaxis or other severe hypersensitivity/allergic reactions occur, initiate appropriate treatment [see Contraindications ( 4 )]. For patients with suspected hypersensitivity to calcitonin salmon, skin testing should be considered prior to treatment utilizing a dilute, sterile solution of calcitonin salmon injection. Healthcare providers may wish to refer patients who require skin testing to an allergist. 5.2 Hypocalcemia Hypocalcemia associated with tetany (i.e., muscle cramps, twitching) and seizure activity has been reported with calcitonin salmon injection therapy. Hypocalcemia must be corrected before initiating therapy. Other disorders affecting mineral metabolism (such as vitamin D deficiency) should also be effectively treated. In patients at risk for hypocalcemia, provisions for parenteral calcium administration should be available during the first several administrations of calcitonin salmon and serum calcium and symptoms of hypocalcemia should be monitored. Use of calcitonin salmon injection for the treatment of Paget's disease or postmenopausal osteoporosis is recommended in conjunction with an adequate intake of calcium and vitamin D [see Dosage and Administration ( 2.5 )]. 5.3 Malignancy In a meta-analysis of 21 randomized, controlled clinical trials with calcitonin salmon (nasal spray or investigational oral formulations), the overall incidence of malignancies reported was higher among calcitonin salmon-treated patients (4.1%) compared with placebo-treated patients (2.9%). This suggests an increased risk of malignancies in calcitonin salmon-treated patients compared to placebo-treated patients. It is not possible to exclude an increased risk when calcitonin salmon is administered long-term subcutaneously, intramuscularly, or intravenously. The benefits for the individual patient should be carefully considered against possible risks [see Adverse Reactions ( 6.1 )]. 5.4 Antibody Formation Circulating antibodies to calcitonin salmon have been reported with Calcitonin salmon injection. The possibility of antibody formation should be considered in any patient with an initial response to Calcitonin salmon injection who later stops responding to treatment [see Adverse Reactions ( 6.3 )]. 5.5 Urine Sediment Abnormalities Coarse granular casts and casts containing renal tubular epithelial cells were reported in young adult volunteers at bed rest who were given injectable calcitonin salmon to study the effect of immobilization on osteoporosis. There was no other evidence of renal abnormality and the urine sediment normalized after calcitonin salmon was stopped. Periodic examinations of urine sediment should be considered."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity The incidence of pituitary adenomas was increased in rats after one and two years of subcutaneous exposure to synthetic calcitonin salmon. The significance of this finding to humans is unknown because pituitary adenomas are very common in rats as they age, the pituitary adenomas did not transform into metastatic tumors, there were no other clear treatment-related neoplasms, and synthetic calcitonin salmon related neoplasms were not observed in mice after two years of dosing. Rat findings The only clear neoplastic finding in rats dosed subcutaneously with calcitonin salmon was an increase in the incidence of pituitary adenomas in male Fisher 344 rats and female Sprague Dawley rats after one year of dosing and male Sprague Dawley rats dosed for one and two years. In female Sprague Dawley rats, the incidence of pituitary adenomas after two years was high in all treatment groups (between 80% and 92% including the control groups) such that a treatment-related effect could not be distinguished from natural background incidence. The lowest dose in male Sprague Dawley rats that developed an increased incidence of pituitary adenomas after two years of dosing (1.7 International Units/kg/day) is approximately 1/6th of the maximum recommended subcutaneous dose in humans (100 International Units/day) based on body surface area conversion between rats and humans. The findings suggest that calcitonin salmon reduced the latency period for development of non-functioning pituitary adenomas. Mouse findings No carcinogenicity potential was evident in male or female mice dosed subcutaneously for two years with synthetic calcitonin salmon at doses up to 800 International Units/kg/day. The 800 International Units/kg/day dose is approximately 39 times the maximum recommended subcutaneous dose in humans (100 International Units/day) based on body surface area conversion between mice and humans. Mutagenesis Synthetic calcitonin salmon tested negative for mutagenicity using Salmonella typhimurium (5 strains) and Escherichia coli (2 strains), with and without rat liver metabolic activation, and was not clastogenic in a chromosome aberration test in Chinese Hamster V79 cells. There was no evidence that calcitonin salmon was clastogenic in the in vivo mouse micronucleus test. Fertility Effects of calcitonin salmon on fertility have not been assessed in animals."],"adverse_reactions_table":["<table ID=\"ID40\" width=\"591\" styleCode=\"Noautorules\"><caption> Table 1: Risk Difference for Malignancies in Calcitonin Salmon-Treated Patients Compared with Placebo-Treated Patients </caption><col width=\"179\"/><col width=\"116\"/><col width=\"148\"/><col width=\"148\"/><tfoot><tr><td align=\"left\" colspan=\"4\"><paragraph styleCode=\"Footnote\"><sup>*</sup>The overall adjusted risk difference is the difference between the percentage of patients who had any malignancy (or malignancy excluding basal cell carcinoma) in calcitonin salmon and placebo</paragraph></td></tr><tr><td align=\"left\" colspan=\"4\"><paragraph styleCode=\"Footnote\">treatment groups, using the Mantel-Haenszel (MH) fixed-effect method. A risk difference of 0 is suggestive of no difference in malignancy risks between the treatment groups.</paragraph></td></tr><tr><td align=\"left\" colspan=\"4\"><paragraph styleCode=\"Footnote\"><sup>&#x2020;</sup>The corresponding 95% confidence interval for the overall adjusted risk difference also based on MH fixed-effect method.</paragraph></td></tr></tfoot><tbody><tr><td valign=\"top\" styleCode=\"Lrule Toprule Botrule Rrule\" align=\"center\"><content styleCode=\"bold\"> Patients</content> </td><td valign=\"top\" styleCode=\" Toprule Botrule Rrule\" align=\"center\"><content styleCode=\"bold\"> Malignancies</content> </td><td valign=\"top\" styleCode=\" Toprule Botrule Rrule\" align=\"center\"><content styleCode=\"bold\"> Risk Difference<sup>*</sup> (%)</content> </td><td valign=\"top\" styleCode=\" Toprule Botrule Rrule\" align=\"center\"><content styleCode=\"bold\"> 95% Confidence Interval<sup>&#x2020;</sup> (%)</content> </td></tr><tr><td valign=\"top\" styleCode=\"Lrule Botrule Rrule\" align=\"left\"> All (nasal spray + oral) </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> All </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> 1.0 </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> (0.3, 1.6) </td></tr><tr><td valign=\"top\" styleCode=\"Lrule Botrule Rrule\" align=\"left\"> All (nasal spray + oral) </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> Excluding basal cell carcinoma </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> 0.5 </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> (-0.1, 1.2) </td></tr><tr><td valign=\"top\" styleCode=\"Lrule Botrule Rrule\" align=\"left\"> All (nasal spray only) </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> All </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> 1.4 </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> (0.3, 2.6) </td></tr><tr><td valign=\"top\" styleCode=\"Lrule Botrule Rrule\" align=\"left\"> All (nasal spray only) </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> Excluding basal cell carcinoma </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> 0.8 </td><td valign=\"top\" styleCode=\" Botrule Rrule\" align=\"center\"> (-0.2, 1.8) </td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Instruct patients and other persons who may administer calcitonin salmon injection in sterile injection technique. Also instruct patients to dispose of needles properly [see Dosage and Administration ( 2.4 )]. Inform patients of the potential increase in risk of malignancy [see Warnings and Precautions ( 5.3 )]. Advise patients with postmenopausal osteoporosis or Paget's disease of bone to maintain an adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day) intake [see Dosage and Administration ( 2.5 )]. Instruct patients to seek emergency medical help or go to the nearest hospital emergency room right away if they develop any signs or symptoms of a serious allergic reaction [see Warnings and Precautions ( 5.1 )]."],"spl_unclassified_section":["Manufactured by: Zydus Lifesciences Ltd. Vadodara - 391510, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534 Rev: 05/23"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Symptomatic Paget's disease of bone: 100 USP Units daily. Ensure adequate calcium and vitamin D intake ( 2.1 , 2.5 ) Hypercalcemia: start with 4 USP Units/kg body weight every 12 hours. Increase to 8 USP Units/kg every 12 hours if no improvement in 1-2 days. Increase further to 8 USP Units/kg every 6 hours if no improvement after 2 more days ( 2.2 ) Postmenopausal osteoporosis: 100 USP Units daily. Ensure adequate calcium and vitamin D intake ( 2.3 , 2.5 ) 2.1 Paget’s Disease of Bone The recommended dose of Calcitonin salmon injection for treatment of symptomatic Paget's disease of bone is 100 USP Units (0.5 mL) per day administered subcutaneously or intramuscularly. 2.2 Hypercalcemia The recommended starting dose of Calcitonin salmon injection for early treatment of hypercalcemia is 4 USP Units/kg body weight every 12 hours by subcutaneous or intramuscular injection. If the response to this dose is not satisfactory after one or two days, the dose may be increased to 8 USP Units/kg every 12 hours. If the response remains unsatisfactory after two more days, the dose may be further increased to a maximum of 8 USP Units/kg every 6 hours. 2.3 Postmenopausal Osteoporosis The recommended dose of Calcitonin salmon injection for treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause is 100 USP Units (0.5 mL) per day administered subcutaneously or intramuscularly. The minimum effective dose of Calcitonin salmon injection for the prevention of vertebral bone mineral density loss has not been established. 2.4 Preparation and Administration Visually inspect calcitonin salmon injection vials. Calcitonin salmon injection is a clear, colorless, solution. If the solution is not clear and colorless, or contains any particles, or if the vial is damaged, do not administer the solution. If the volume of calcitonin salmon injection to be injected exceeds 2 mL, intramuscular injection is preferable and the total dose should be distributed across multiple sites of injection. Instruct patients to use sterile injection technique when administering calcitonin salmon injection, and to dispose of needles properly. 2.5 Recommendations for Calcium and Vitamin D Supplementation Patients who use calcitonin salmon injection for treatment of postmenopausal osteoporosis should receive adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day)."],"spl_product_data_elements":["CALCITONIN SALMON CALCITONIN SALMON CALCITONIN SALMON CALCITONIN SALMON ACETIC ACID PHENOL SODIUM ACETATE SODIUM CHLORIDE WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Calcitonin salmon injection, USP, synthetic is available as a clear, colorless, sterile solution of synthetic calcitonin salmon, USP in individual 2 mL multiple-dose vials containing 200 USP Units per mL. Injection: 200 USP Units per mL sterile solution in 2 mL multiple-dose vials ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS There are no data to support use in children ( 8.4 ) 8.1 Pregnancy Risk Summary There are no studies with calcitonin salmon injection in pregnant women to inform a drug associated risk for birth defects or miscarriage. In an animal reproduction study, subcutaneous administration of calcitonin salmon to pregnant rabbits during organogenesis at 4-18 times the recommended parenteral human dose caused a decrease in fetal birth weights. No adverse developmental outcome was observed in the rat with subcutaneous administration of calcitonin salmon at 9 times the recommended human parenteral dose based on body surface area (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Calcitonin salmon has been shown to cause a decrease in fetal birth weights in rabbits when given by subcutaneous injection in doses 4 to 18 times the parenteral dose recommended for human use (of 54 International Units/m 2 ). No embryo/fetal toxicities related to calcitonin salmon were reported from maternal subcutaneous daily doses in rats up to 80 International Units/kg/day from gestation day 6 to 15. 8.2 Lactation Risk Summary There is no information on the presence of calcitonin salmon in human milk, the effects on the breastfed child, or the effects on milk production. Calcitonin has been shown to inhibit lactation in rats. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for calcitonin salmon injection and any potential adverse effects on the breastfed infant from calcitonin salmon injection or from the underlying maternal condition. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of calcitonin salmon injection did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70710-1875-1 Calcitonin Salmon Injection, USP, Synthetic 400 USP Units/2 mL (200 USP Units/mL) For Intramuscular or Subcutaneous Use 2 mL Multiple-Dose vial Rx only vial-label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity The incidence of pituitary adenomas was increased in rats after one and two years of subcutaneous exposure to synthetic calcitonin salmon. The significance of this finding to humans is unknown because pituitary adenomas are very common in rats as they age, the pituitary adenomas did not transform into metastatic tumors, there were no other clear treatment-related neoplasms, and synthetic calcitonin salmon related neoplasms were not observed in mice after two years of dosing. Rat findings The only clear neoplastic finding in rats dosed subcutaneously with calcitonin salmon was an increase in the incidence of pituitary adenomas in male Fisher 344 rats and female Sprague Dawley rats after one year of dosing and male Sprague Dawley rats dosed for one and two years. In female Sprague Dawley rats, the incidence of pituitary adenomas after two years was high in all treatment groups (between 80% and 92% including the control groups) such that a treatment-related effect could not be distinguished from natural background incidence. The lowest dose in male Sprague Dawley rats that developed an increased incidence of pituitary adenomas after two years of dosing (1.7 International Units/kg/day) is approximately 1/6th of the maximum recommended subcutaneous dose in humans (100 International Units/day) based on body surface area conversion between rats and humans. The findings suggest that calcitonin salmon reduced the latency period for development of non-functioning pituitary adenomas. Mouse findings No carcinogenicity potential was evident in male or female mice dosed subcutaneously for two years with synthetic calcitonin salmon at doses up to 800 International Units/kg/day. The 800 International Units/kg/day dose is approximately 39 times the maximum recommended subcutaneous dose in humans (100 International Units/day) based on body surface area conversion between mice and humans. Mutagenesis Synthetic calcitonin salmon tested negative for mutagenicity using Salmonella typhimurium (5 strains) and Escherichia coli (2 strains), with and without rat liver metabolic activation, and was not clastogenic in a chromosome aberration test in Chinese Hamster V79 cells. There was no evidence that calcitonin salmon was clastogenic in the in vivo mouse micronucleus test. Fertility Effects of calcitonin salmon on fertility have not been assessed in animals."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"Injectable","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Sanofi Aventis Us","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"lithium","severity":"moderate","mechanism":"increased urinary clearance of lithium","management":"The dose of lithium may require adjustment","clinicalEffect":"reduction in plasma lithium concentrations"}],"commonSideEffects":[{"effect":"nausea with or without vomiting","drugRate":"10%","_validated":true,"placeboRate":""},{"effect":"injection site inflammation","drugRate":"10%","_validated":true,"placeboRate":""},{"effect":"flushing of the face or hands","drugRate":"2% to 5%","_validated":true,"placeboRate":""}],"contraindications":["Hypersensitivity to calcitonin salmon or any of the excipients. Reactions have included anaphylaxis with death, bronchospasm, and swelling of the tongue or throat."],"seriousAdverseEvents":[{"event":"malignancies","detail":"overall incidence in calcitonin salmon-treated patients compared with placebo-treated patients (2.9%) in a meta-analysis of 21 trials","severity":"serious","incidence":"4.1%"},{"event":"malignancies (excluding basal cell carcinoma)","detail":"incidence in calcitonin salmon-treated patients (nasal spray only) compared with placebo-treated patients (2.3%) in a meta-analysis of 18 trials","severity":"serious","incidence":"4.5%"}]},"trials":[],"aliases":[],"company":"Sanofi Aventis Us","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CALCITONIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:04:33.867908+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Calcitonin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T06:04:50.678596+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:06:32.783573+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALCITONIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:04:50.076156+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:04:31.795503+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:04:31.795569+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:06:24.329313+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:04:31.795583+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, alt","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:05:09.466413+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Calcitonin receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:04:50.678160+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:05:39.958196+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594242/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:04:50.549740+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity Reactions, including anaphylaxis [see Warnings and Precautions ( 5.1 )] Hypocalcemia [see Warnings and Precautions ( 5.2 )] Malignancy [see Warnings and Precautions ( 5.3 )] Most common adverse reactions are nausea with or without vomiting (10%), injection site inflammation (10%), and flushing of the face or hands (2% to 5%) ( 6 ) To report SUSPECTED ADVERS","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:05:28.860598+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:05:33.485969+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA215864","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:04:31.795592+00:00"}},"allNames":"osteobios","offLabel":[],"synonyms":["Osteobios","CALCITONIN HUMAN"],"timeline":[{"date":"1986-07-03","type":"positive","source":"FDA Orange Book","milestone":"Miacalcin approved — 100 IU/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1995-08-17","type":"positive","source":"FDA Orange Book","milestone":"Miacalcin approved — 200 IU/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2024-04-11","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 5 manufacturers approved"},{"date":"2025-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Amneal to Sanofi Aventis Us"},{"date":"20250926","type":"positive","source":"OpenFDA","milestone":"FDA approval (Amneal)"}],"aiSummary":"Calcitonin (Osteobios), marketed by Sanofi Aventis US, is a calcitonin receptor agonist primarily indicated for symptomatic Paget's disease of bone. The drug's key strength lies in its well-established mechanism of action and its current market presence, with a key composition patent expiring in 2028. The primary risk is the lack of significant revenue data and key trial results, which may limit its competitive edge against other treatments.","approvals":[{"date":"20250926","orphan":false,"company":"AMNEAL","regulator":"FDA"}],"brandName":"Osteobios","ecosystem":[],"mechanism":{"target":"calcitonin receptor","modality":"Peptide","drugClass":"Calcitonin [EPC]","explanation":"Calcitonin salmon is a calcitonin receptor agonist that mainly influences bone, though it also affects the kidneys and gastrointestinal tract. It has similar actions to mammalian calcitonins but is more potent and has a longer duration of action. Its exact role in bone physiology is not fully understood, but receptors have been found in osteoclasts and osteoblasts.","oneSentence":"Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract.","technicalDetail":"Calcitonin salmon binds to calcitonin receptors, which are present in osteoclasts and osteoblasts. This binding leads to various physiological effects, primarily on bone, but also on the kidneys and gastrointestinal tract. The specific signaling pathways and full extent of its actions on bone are not yet fully elucidated."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Calcitonin","title":"Calcitonin","extract":"Calcitonin is a 32 amino acid peptide hormone secreted by parafollicular cells (also known as C cells) of the thyroid (or endostyle) in humans and other chordates in the ultimopharyngeal body. It acts to reduce blood calcium (Ca2+), opposing the effects of parathyroid hormone (PTH)."},"commercial":{"launchDate":"2025","_launchSource":"OpenFDA (20250926, AMNEAL)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"CALCITONIN\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"CALCITONIN\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=calcitonin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=calcitonin","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://en.wikipedia.org/wiki/Calcitonin","fields":["history","overview"],"source":"Wikipedia"},{"id":6,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:23:00.330197","_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T06:06:32.784094+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"calcitonin","indications":{"approved":[{"id":"calcitonin-symptomatic-paget's-disease-of","name":"Symptomatic Paget's disease of bone","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with symptomatic Paget's disease of bone, moderate to severe disease, polyostotic involvement, elevated serum alkaline phosphatase and urinary hydroxyproline excretion, who do not respond to or are unsuitable for alternative treatments","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with symptomatic Paget's disease of bone, moderate to severe disease, polyostotic involvement, elevated serum alkaline phosphatase and urinary hydroxyproline excretion, who do not respond to or are unsuitable for alternative treatments","diagnosticRequired":"Elevated serum alkaline phosphatase and urinary hydroxyproline excretion","brandNameForIndication":"Osteobios"},{"id":"calcitonin-hypercalcemia","name":"Hypercalcemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with hypercalcemic emergencies requiring a rapid decrease in serum calcium","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with hypercalcemic emergencies requiring a rapid decrease in serum calcium","diagnosticRequired":null,"brandNameForIndication":"Osteobios"},{"id":"calcitonin-postmenopausal-osteoporosis","name":"Postmenopausal osteoporosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Women greater than 5 years postmenopause with postmenopausal osteoporosis, for whom alternative treatments are not suitable","pivotalTrial":null,"restrictions":[],"patientPopulation":"Women greater than 5 years postmenopause with postmenopausal osteoporosis, for whom alternative treatments are not suitable","diagnosticRequired":null,"brandNameForIndication":"Osteobios"}],"offLabel":[],"pipeline":[]},"currentOwner":"Sanofi Aventis Us","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT07261371","phase":"PHASE1","title":"A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-24","conditions":["Healthy Volunteer"],"enrollment":64,"completionDate":"2026-05-13"},{"nctId":"NCT06330168","phase":"NA","title":"Paravertebral Calcitonin in Thoracotomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tanta University","startDate":"2024-03-28","conditions":["Calcitonin","Paravertebral","Thoracotomy"],"enrollment":92,"completionDate":"2026-05-15"},{"nctId":"NCT03898856","phase":"PHASE4","title":"Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-04-01","conditions":["Chronic Diarrhea of Unknown Origin"],"enrollment":93,"completionDate":"2025-01-30"},{"nctId":"NCT07330024","phase":"","title":"Evaluation of Pulpal and Salivary Neuropeptides in Dental Pain","status":"COMPLETED","sponsor":"Kahramanmaras Sutcu Imam University","startDate":"2024-11-01","conditions":["Dental Pain","Pulpitis","Pulpal Inflammation","Psychological Stress","Anxiety"],"enrollment":72,"completionDate":"2025-11-15"},{"nctId":"NCT05217927","phase":"PHASE4","title":"Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-04","conditions":["Migraine"],"enrollment":1415,"completionDate":"2024-12-11"},{"nctId":"NCT02856347","phase":"NA","title":"Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2017-03-22","conditions":["Medullary Thyroid Cancer"],"enrollment":24,"completionDate":"2020-12-20"},{"nctId":"NCT01977079","phase":"NA","title":"Procalcitonin and Threatened Premature Delivery","status":"TERMINATED","sponsor":"Centre Hospitalier Departemental Vendee","startDate":"2013-12","conditions":["Pregnancy","Premature Delivery"],"enrollment":131,"completionDate":"2016-07"},{"nctId":"NCT07203248","phase":"","title":"Chinese Real-world Study of Treatment of Vestibular Migraine","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12","conditions":["Vestibular Migraine","Dizziness","Vertigo"],"enrollment":2000,"completionDate":"2028-12"},{"nctId":"NCT07159750","phase":"","title":"Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2024-01-02","conditions":["Migraine","Episodic Migraine","Chronic Migraine, Headache"],"enrollment":700,"completionDate":"2026-01"},{"nctId":"NCT05293366","phase":"","title":"LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions","status":"RECRUITING","sponsor":"Federico II University","startDate":"2022-01-27","conditions":["Long Covid-19"],"enrollment":100,"completionDate":"2027-01-27"},{"nctId":"NCT07021859","phase":"NA","title":"Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide","status":"RECRUITING","sponsor":"Danish Headache Center","startDate":"2025-06-27","conditions":["Migraine Aura","Migraine With Aura"],"enrollment":21,"completionDate":"2026-12-30"},{"nctId":"NCT07103694","phase":"","title":"i-NEED: NEw migrainE Drugs Database","status":"RECRUITING","sponsor":"IRCCS San Raffaele Roma","startDate":"2022-03-24","conditions":["Episodic Migraine","Chronic Migraine","Medication Overuse Headache"],"enrollment":2641,"completionDate":"2025-12-31"},{"nctId":"NCT07029373","phase":"","title":"Plasma Calcitonin Gene-Related Peptide (CGRP) Levels in Patients With Head and Neck Malignancies Undergoing Radiotherapy","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-07-04","conditions":["Head and Neck Cancer"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT07033104","phase":"NA","title":"Adding Calcitonin to Bupivacaine in Transversalis Fascia Plane Block for Cesarean Section","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-04-01","conditions":["Transversalis Fascia Plane Block"],"enrollment":70,"completionDate":"2025-09-01"},{"nctId":"NCT05805683","phase":"NA","title":"Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-05-01","conditions":["Calcitonin","Neuropathic Pain","Spinal Cord Injury"],"enrollment":50,"completionDate":"2027-05-01"},{"nctId":"NCT05570149","phase":"","title":"EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.","status":"RECRUITING","sponsor":"IRCCS San Raffaele Roma","startDate":"2023-01-01","conditions":["Migraine Disorders"],"enrollment":500,"completionDate":"2026-12-31"},{"nctId":"NCT04445857","phase":"PHASE4","title":"Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Tramadol-abuse Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-09-01","conditions":["Analgesia"],"enrollment":90,"completionDate":"2021-01-31"},{"nctId":"NCT03919266","phase":"NA","title":"Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-06-02","conditions":["Acute Chest Syndrome","Sickle Cell Disease"],"enrollment":72,"completionDate":"2022-10-10"},{"nctId":"NCT05127980","phase":"","title":"Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-10-15","conditions":["Epstein-Barr Virus (EBV) Infection"],"enrollment":80,"completionDate":"2026-12"},{"nctId":"NCT02088645","phase":"PHASE1","title":"177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2015-04","conditions":["Thyroid Cancer, Medullary","Neuroendocrine Tumor of the Lung Grade 1 and 2","Neuroendocrine Tumor of the Thymus Grade 1 and 2","Neuroendocrine Tumor GEP Grade 1-3"],"enrollment":24,"completionDate":"2027-06"},{"nctId":"NCT06833749","phase":"PHASE2","title":"Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis","status":"RECRUITING","sponsor":"KeyBioscience AG","startDate":"2025-01-28","conditions":["Osteoarthritis in the Knee","Obesity"],"enrollment":600,"completionDate":"2026-12"},{"nctId":"NCT06004388","phase":"PHASE3","title":"Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)","status":"COMPLETED","sponsor":"Click Therapeutics, Inc.","startDate":"2023-07-21","conditions":["Migraine","Episodic Migraine","Headache","Headache, Migraine"],"enrollment":110,"completionDate":"2024-06-05"},{"nctId":"NCT04628429","phase":"","title":"CGRP Inhibition, Autonomic Function, and Migraine","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2020-10-01","conditions":["Episodic Migraine","Chronic Migraine"],"enrollment":120,"completionDate":"2026-12"},{"nctId":"NCT05955612","phase":"PHASE3","title":"Use of Procalcitonin, a Blood Test to Guide Antibiotic Therapy for Sepsis in Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2023-07-26","conditions":["Sepsis"],"enrollment":532,"completionDate":"2024-07-30"},{"nctId":"NCT06662461","phase":"NA","title":"Ultrasound Guided Block of Stellate Ganglion Versus Greater Occipital Nerve in Resistant Migraine and Correlation to Calcitonin Gene Related Peptide","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-02-01","conditions":["Migraine"],"enrollment":40,"completionDate":"2025-03"},{"nctId":"NCT03935984","phase":"PHASE4","title":"Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity","status":"RECRUITING","sponsor":"Joseph Sferra","startDate":"2019-05-29","conditions":["Primary Hyperparathyroidism","Hypercalcemia"],"enrollment":37,"completionDate":"2026-12-31"},{"nctId":"NCT06549270","phase":"","title":"Biochemical Profiling of Migraine Patients","status":"RECRUITING","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2023-05-10","conditions":["Migraine Disorders","Chronic Migraine","Episodic Migraine"],"enrollment":100,"completionDate":"2026-05"},{"nctId":"NCT06562400","phase":"","title":"Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments","status":"RECRUITING","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2023-05-10","conditions":["Migraine Disorders","Chronic Migraine","Episodic Migraine"],"enrollment":45,"completionDate":"2026-05"},{"nctId":"NCT06562413","phase":"","title":"Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments","status":"RECRUITING","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2023-05-10","conditions":["Migraine Disorders","Chronic Migraine","Episodic Migraine"],"enrollment":100,"completionDate":"2026-05"},{"nctId":"NCT06510751","phase":"","title":"Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P","status":"RECRUITING","sponsor":"Melike Cengiz","startDate":"2024-03-01","conditions":["Meningitis","Diagnosis","Prognosis"],"enrollment":51,"completionDate":"2025-08-30"},{"nctId":"NCT01856920","phase":"PHASE2","title":"QUILT-3.006 for Recurrent Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"NantCell, Inc.","startDate":"2013-03-26","conditions":["Medullary Thyroid Cancer (MTC)"],"enrollment":35,"completionDate":"2018-05-08"},{"nctId":"NCT03812991","phase":"PHASE4","title":"The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2019-07-01","conditions":["Pelvic Ring Fractures"],"enrollment":21,"completionDate":"2023-02-28"},{"nctId":"NCT05895500","phase":"","title":"Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia","status":"COMPLETED","sponsor":"Nvision Laser Eye Centers","startDate":"2023-05-10","conditions":["Dry Eye","Asthenopia"],"enrollment":103,"completionDate":"2023-11-09"},{"nctId":"NCT05284019","phase":"PHASE4","title":"Real World Effectiveness of Eptinezumab in Participants With Migraine","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2022-03-04","conditions":["Migraine"],"enrollment":32,"completionDate":"2023-04-14"},{"nctId":"NCT05812742","phase":"NA","title":"Chasing Biomarkers in Post-concussion Syndrome","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-03","conditions":["Post Concussive Symptoms"],"enrollment":86,"completionDate":"2023-07"},{"nctId":"NCT05162027","phase":"PHASE2","title":"Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2022-05-26","conditions":["Temporomandibular Disorders"],"enrollment":5,"completionDate":"2023-01-03"},{"nctId":"NCT05142228","phase":"PHASE2","title":"Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2022-05-31","conditions":["Trigeminal Neuropathy"],"enrollment":5,"completionDate":"2022-10-27"},{"nctId":"NCT05632133","phase":"PHASE3","title":"The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-06-01","conditions":["Effect of Drug","Migraine Disorders"],"enrollment":200,"completionDate":"2023-08-10"},{"nctId":"NCT06267664","phase":"","title":"Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)","status":"UNKNOWN","sponsor":"Hospital Clínico Universitario de Valladolid","startDate":"2023-12-04","conditions":["Migraine","Migraine Disorders","Migraine With Aura","Headache Disorders"],"enrollment":1500,"completionDate":"2024-12-01"},{"nctId":"NCT05785988","phase":"","title":"Anti-CGRP Monoclonal Antibody Response After Switching (AMARAS)","status":"UNKNOWN","sponsor":"Hospital Clínico Universitario de Valladolid","startDate":"2019-11-01","conditions":["Migraine","Head Pain"],"enrollment":600,"completionDate":"2024-11-10"},{"nctId":"NCT06256198","phase":"","title":"Role of PCO2 Gap as Predictor of Clinical Outcome in ICU Septic Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2024-02","conditions":["Sepsis"],"enrollment":80,"completionDate":"2024-06"},{"nctId":"NCT04218539","phase":"PHASE1","title":"Repeat Dosing of Psilocybin in Migraine Headache","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-08-10","conditions":["Migraine Headache"],"enrollment":18,"completionDate":"2023-11-05"},{"nctId":"NCT05804500","phase":"NA","title":"RecoveryPlus Telerehab Platform Pilot Study","status":"COMPLETED","sponsor":"NODEHealth Foundation","startDate":"2023-03-27","conditions":["Heart Diseases","Angina, Stable","Angina Pectoris","Myocardial Ischemia","Myocardial Infarction","Coronary Artery Disease","Coronary Artery Stenosis","Valve Heart Disease","Valve Disease, Heart"],"enrollment":75,"completionDate":"2024-01-15"},{"nctId":"NCT06155123","phase":"","title":"HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2020-01-14","conditions":["Migraine Disorders","Chronic Migraine","Episodic Migraine"],"enrollment":60,"completionDate":"2024-06"},{"nctId":"NCT04796766","phase":"NA","title":"Human Electrophysiological Model to Quantify the CGRP-related Axon Reflex of Trigeminal Afferents","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2021-02-01","conditions":["Migraine"],"enrollment":72,"completionDate":"2024-12"},{"nctId":"NCT05635604","phase":"NA","title":"Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2023-03-01","conditions":["Migraine"],"enrollment":38,"completionDate":"2023-08-04"},{"nctId":"NCT03921788","phase":"","title":"Neuropeptides and Venous Pelvic Pain","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2019-04-01","conditions":["Pelvic Pain","Varicose Veins Pelvic","Pelvic Congestion Syndrome"],"enrollment":120,"completionDate":"2022-02-11"},{"nctId":"NCT06067594","phase":"","title":"Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.","status":"COMPLETED","sponsor":"Austral University, Argentina","startDate":"2018-03-01","conditions":["Medullary Thyroid Carcinoma","Nodular Goiter"],"enrollment":155,"completionDate":"2022-06-01"},{"nctId":"NCT05492695","phase":"PHASE4","title":"Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study","status":"TERMINATED","sponsor":"Diamond Headache Clinic","startDate":"2022-10-01","conditions":["Migraine"],"enrollment":2,"completionDate":"2023-09-28"},{"nctId":"NCT04064814","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2019-09-14","conditions":["Adolescent Migraine"],"enrollment":60,"completionDate":"2021-06-30"},{"nctId":"NCT05366621","phase":"","title":"Post-fracture Medication and Mortality","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-11-01","conditions":["Osteoporosis","Osteoporosis Fracture","Drug Therapy","Mortality","Adherence, Medication"],"enrollment":216155,"completionDate":"2021-10-31"},{"nctId":"NCT05796115","phase":"NA","title":"PROcalcitonin and Presepsin-guided Decision for Antibiotic Prophylaxis of EOS","status":"UNKNOWN","sponsor":"University of Florence","startDate":"2023-04-01","conditions":["Early-Onset Neonatal Sepsis"],"enrollment":266,"completionDate":"2025-09-30"},{"nctId":"NCT05768828","phase":"","title":"Stimulation-evoked Calcitonin Gene-Related Peptide (CGRP) as Biomarker of Migraine","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2023-02-20","conditions":["Migraine"],"enrollment":20,"completionDate":"2023-07-30"},{"nctId":"NCT05692297","phase":"NA","title":"Denosumab Treatment in CKD Patients at High Risk of Fracture","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2023-01-01","conditions":["Chronic Kidney Diseases","Fracture","Bone Density, Low","End Stage Renal Disease"],"enrollment":102,"completionDate":"2025-12-31"},{"nctId":"NCT04592952","phase":"PHASE4","title":"Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab","status":"UNKNOWN","sponsor":"Danish Headache Center","startDate":"2020-10-08","conditions":["Migraine"],"enrollment":400,"completionDate":"2025-08-01"},{"nctId":"NCT03737916","phase":"NA","title":"The Effect of Perineural Dextrose Injection in Patients With Ulnar Neuropathy at the Elbow","status":"COMPLETED","sponsor":"Ankara Education and Research Hospital","startDate":"2018-11-18","conditions":["Ulnar Neuropathies"],"enrollment":60,"completionDate":"2020-11-18"},{"nctId":"NCT02466334","phase":"NA","title":"CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2015-06","conditions":["Cluster Headache"],"enrollment":37,"completionDate":"2018-12"},{"nctId":"NCT01924052","phase":"NA","title":"CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2013-06","conditions":["Migraine Without Aura"],"enrollment":40,"completionDate":"2013-08"},{"nctId":"NCT05442008","phase":"","title":"Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment","status":"COMPLETED","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2018-12-01","conditions":["Migraine"],"enrollment":53,"completionDate":"2021-01-01"},{"nctId":"NCT04260087","phase":"","title":"New Daily Persistent Headache Biomarkers Study","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2018-05-01","conditions":["New Daily Persistent Headache","New Daily Persistent Headache (NDPH)"],"enrollment":8,"completionDate":"2021-11-18"},{"nctId":"NCT03342001","phase":"PHASE4","title":"Hypothyroidism Treated With Calcitonin","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-06-18","conditions":["Hypothyroidism"],"enrollment":11,"completionDate":"2019-08-14"},{"nctId":"NCT03647657","phase":"EARLY_PHASE1","title":"177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2018-12-13","conditions":["Thyroid Cancer, Medullary"],"enrollment":8,"completionDate":"2021-12-14"},{"nctId":"NCT02621931","phase":"PHASE3","title":"Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-03-22","conditions":["Migraine"],"enrollment":1130,"completionDate":"2017-04-11"},{"nctId":"NCT02629861","phase":"PHASE3","title":"Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-03-23","conditions":["Migraine"],"enrollment":875,"completionDate":"2017-04-10"},{"nctId":"NCT03828539","phase":"PHASE4","title":"Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-22","conditions":["Migraine"],"enrollment":777,"completionDate":"2020-07-29"},{"nctId":"NCT03333109","phase":"PHASE3","title":"Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-08","conditions":["Episodic Migraine"],"enrollment":900,"completionDate":"2020-01-13"},{"nctId":"NCT04993456","phase":"","title":"Calcitonin Level and New-onset of Post-Operative Atrial Fibrillation","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-06-15","conditions":["Calcitonin Secretion Disorder","Post-operative Atrial Fibrillation"],"enrollment":200,"completionDate":"2024-07-15"},{"nctId":"NCT01250574","phase":"","title":"Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections","status":"COMPLETED","sponsor":"University Hospital, Akershus","startDate":"2010-11","conditions":["Bacterial Infection","Postoperative Infection","Abdominal Infection"],"enrollment":173,"completionDate":"2017-12"},{"nctId":"NCT04334850","phase":"NA","title":"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-20","conditions":["Covid19","Pneumonia"],"enrollment":194,"completionDate":"2021-06-23"},{"nctId":"NCT03630120","phase":"PHASE2","title":"Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-08-06","conditions":["Thyroid Cancer","Thyroid Cancer, Medullary","Differentiated Thyroid Cancer","Papillary Thyroid Cancer","Follicular Thyroid Cancer","Poorly Differentiated Thyroid Gland Carcinoma"],"enrollment":6,"completionDate":"2019-12-05"},{"nctId":"NCT04019496","phase":"","title":"Neurophysiology of Prophylactic Treatment in Migraine","status":"COMPLETED","sponsor":"University Medicine Greifswald","startDate":"2019-01-29","conditions":["Migraine"],"enrollment":44,"completionDate":"2021-05-02"},{"nctId":"NCT04881786","phase":"NA","title":"Calcitonin Gene-related Peptide Expression in Human Periodontal Ligament","status":"COMPLETED","sponsor":"Institucion Universitaria Colegios de Colombia","startDate":"2019-06-04","conditions":["CGRP Expression in Human Periodontal Ligament"],"enrollment":90,"completionDate":"2020-03-10"},{"nctId":"NCT04452929","phase":"NA","title":"The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients","status":"UNKNOWN","sponsor":"Danish Headache Center","startDate":"2020-07-22","conditions":["Migraine","Migraine Without Aura","Migraine With Aura"],"enrollment":72,"completionDate":"2022-07"},{"nctId":"NCT03401619","phase":"","title":"Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2017-09-21","conditions":["Osteoporosis，Neurological Disorders"],"enrollment":2000,"completionDate":"2027-09-22"},{"nctId":"NCT03791515","phase":"NA","title":"Clinical Characteristics and Pathophysiology of Post-Traumatic Headache","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2018-07-26","conditions":["Post-Traumatic Headache","Concussion, Mild"],"enrollment":200,"completionDate":"2019-12-01"},{"nctId":"NCT03542357","phase":"NA","title":"The Effect of Sumatriptan and Placebo on CGRP Induced Headache","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2018-02-15","conditions":["Migraine"],"enrollment":30,"completionDate":"2018-09-01"},{"nctId":"NCT03053999","phase":"","title":"Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)","status":"UNKNOWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-09","conditions":["Multiple Endocrine Neoplasia","Pancreatic Neuroendocrine Tumors","Hyperparathyroidism"],"enrollment":53,"completionDate":"2023-10"},{"nctId":"NCT00486434","phase":"PHASE3","title":"Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Nordic Bioscience A/S","startDate":"2007-05","conditions":["Osteoarthritis"],"enrollment":1176,"completionDate":"2010-09"},{"nctId":"NCT00704847","phase":"PHASE3","title":"Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)","status":"TERMINATED","sponsor":"Nordic Bioscience A/S","startDate":"2008-06","conditions":["Osteoarthritis"],"enrollment":1030,"completionDate":"2011-06"},{"nctId":"NCT03923803","phase":"","title":"Diagnostic Values of C-reactive Protein and Procalcitonin in Predicting Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-07","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":90,"completionDate":"2020-10"},{"nctId":"NCT01315847","phase":"PHASE1","title":"Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01-14","conditions":["Migraine"],"enrollment":10,"completionDate":"2011-07-26"},{"nctId":"NCT03143465","phase":"NA","title":"Pharmacologically Triggered Migraine Without Aura and Neuroimaging","status":"UNKNOWN","sponsor":"Danish Headache Center","startDate":"2016-08","conditions":["Migraine With Aura"],"enrollment":36,"completionDate":"2019-05"},{"nctId":"NCT02898948","phase":"","title":"Procalcitonin (PCT) as a Diagnostic Marker of Bacterial Infection in the Patients Admitted for Fever and/or Inflammatory Syndrome to the Internal Medicine Department","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2016-02-11","conditions":["Systemic Inflammatory Response Syndrome","Fever"],"enrollment":116,"completionDate":"2016-10-18"},{"nctId":"NCT02130986","phase":"NA","title":"Procalcitonin Antibiotic Consensus Trial (ProACT)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2014-11-03","conditions":["Lower Respiratory Tract Infection (LRTI)"],"enrollment":1664,"completionDate":"2017-07-21"},{"nctId":"NCT01294709","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-12","conditions":["Angina Pectoris","Coronary Heart Disease","Calcitonin Gene-related Peptide Receptor"],"enrollment":64,"completionDate":"2009-03-13"},{"nctId":"NCT03636945","phase":"NA","title":"Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2018-10","conditions":["Medullary Thyroid Carcinoma"],"enrollment":62,"completionDate":"2021-09"},{"nctId":"NCT02392689","phase":"NA","title":"Improve Management of Heart Failure With Procalcitonin","status":"TERMINATED","sponsor":"Brahms AG","startDate":"2015-03","conditions":["Heart Failure","Infection"],"enrollment":759,"completionDate":"2018-04-14"},{"nctId":"NCT03557541","phase":"NA","title":"Sardine-enriched Diet for Prevention Type 2 Diabetes","status":"COMPLETED","sponsor":"Institut d'Investigacions Biomèdiques August Pi i Sunyer","startDate":"2014-05","conditions":["Diabetes Mellitus, Type 2","PreDiabetes","Diet Habit","Diabetes","Nutritional and Metabolic Disease"],"enrollment":182,"completionDate":"2017-07"},{"nctId":"NCT02085733","phase":"","title":"Pro-calcitonin for Early Detection of Septic Arthritis","status":"COMPLETED","sponsor":"Children's Hospitals and Clinics of Minnesota","startDate":"2014-02","conditions":["Arthritis, Infectious"],"enrollment":150,"completionDate":"2016-12-31"},{"nctId":"NCT03481400","phase":"NA","title":"CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment","status":"UNKNOWN","sponsor":"Danish Headache Center","startDate":"2016-07","conditions":["Migraine"],"enrollment":40,"completionDate":"2019-09"},{"nctId":"NCT00478335","phase":"NA","title":"Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":["Nephrogenic Diabetes Insipidus"],"enrollment":4,"completionDate":"2012-10"},{"nctId":"NCT03223233","phase":"","title":"Predicting the Severity of Post-cesarean Wound Infections Using Serum Procalcitonin Levels","status":"COMPLETED","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2017-05-02","conditions":["Wound Infection","Cesarean Wound Disruption"],"enrollment":90,"completionDate":"2017-10-08"},{"nctId":"NCT01652573","phase":"NA","title":"Calcitonin for Treating X-linked Hypophosphatemia","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-03","conditions":["Hypophosphatemic Rickets, X Linked Dominant"],"enrollment":21,"completionDate":"2015-09"},{"nctId":"NCT03058718","phase":"NA","title":"Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2014-01-01","conditions":["Procalcitonin","Bronchiectasis","Antibiotic Therapy"],"enrollment":210,"completionDate":"2017-02-01"},{"nctId":"NCT02115360","phase":"NA","title":"Epidural Calcitonin in Lower Limb Amputation","status":"COMPLETED","sponsor":"Tanta University","startDate":"2014-04","conditions":["Amputation Stumps"],"enrollment":60,"completionDate":"2016-08"},{"nctId":"NCT02881892","phase":"","title":"Iplasma IL6, Procalcitonin and VEGF and Dialysate Level in CAPD Patients","status":"COMPLETED","sponsor":"Bangkok Metropolitan Administration Medical College and Vajira Hospital","startDate":"2012-03","conditions":["Chronic Kidney Disease"],"enrollment":26,"completionDate":"2014-06"},{"nctId":"NCT00688077","phase":"NA","title":"FGF-23 Suppressibility by Calcitonin","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2008-05","conditions":["Hypophosphatemia"],"enrollment":49,"completionDate":""},{"nctId":"NCT00754884","phase":"PHASE4","title":"Calcitonin in the Treatment of Fibromyalgia","status":"WITHDRAWN","sponsor":"Unidad de Investigacion en Enfermedades Cronico-Degenerativas","startDate":"2008-10","conditions":["Fibromyalgia"],"enrollment":0,"completionDate":"2009-02"},{"nctId":"NCT00987818","phase":"NA","title":"Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU","status":"WITHDRAWN","sponsor":"Rijnstate Hospital","startDate":"","conditions":["Sepsis","Intensive Care"],"enrollment":0,"completionDate":""},{"nctId":"NCT02519998","phase":"","title":"Tissue Repository and Master Database for Concussion Biomarker and Risk Calculator Development","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2015-03","conditions":["Brain Concussion"],"enrollment":1000,"completionDate":"2016-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injectable","formulations":[{"form":"INJECTABLE","route":"ORAL","productName":""}]},"_patentsChecked":true,"crossReferences":{"UNII":"I0IO929019","SPL_ID":"ed712a71-07a8-02bc-e053-2995a90a8c42","chemblId":"CHEMBL4594242"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2025-","companyName":"Amneal","relationship":"Original Developer"},{"period":"present","companyName":"Sanofi Aventis Us","relationship":"Current Owner"}],"publicationCount":29407,"therapeuticAreas":["Metabolic"],"applicationNumber":"ANDA216294","biosimilarFilings":[],"originalDeveloper":"Amneal","recentPublications":[{"date":"2026 Mar 28","pmid":"41911648","title":"Insight into the interaction of heme with human calcitonin (hCT) and its inhibitory effect on hCT aggregation.","journal":"Journal of inorganic biochemistry"},{"date":"2026 Mar 30","pmid":"41906924","title":"The Role of Calcitonin Gene-Related Peptide in High-Altitude Headache: A Prospective Field Study.","journal":"Annals of clinical and translational neurology"},{"date":"2026 Mar 28","pmid":"41896726","title":"Efficacy of coadministration of calcitonin and hyperbaric bupivacaine in spinal anesthesia for unilateral open inguinal hernia repair in tramadol abuse patients: a randomized controlled trial.","journal":"BMC anesthesiology"},{"date":"2026 Mar 27","pmid":"41896381","title":"Proteomic profiling and pathway analyses reveal molecular signatures and immune networks in pediatric sepsis.","journal":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]"},{"date":"2026 Feb 25","pmid":"41892600","title":"Predictors of Response to Occipital Nerve Stimulation in Patients with Refractory Chronic Cluster Headache: Protocol for a Prospective Observational Study.","journal":"Brain sciences"}],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Amneal","Apotex Inc","Cipla","Custopharm Inc","Dr Reddys","Fresenius Kabi Usa","Igi Labs Inc","Ph Health","Sagent","Zydus Pharms"],"status":"withdrawn","companyName":"Sanofi Aventis Us","companyId":"sanofi","modality":"Recombinant protein","firstApprovalDate":"2025","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"AMNEAL","brand_name_local":null,"application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T06:06:32.784094+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}